Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Return on Capital Employed (2021 - 2025)

Historic Return on Capital Employed for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to 0.07%.

  • Kiniksa Pharmaceuticals International's Return on Capital Employed rose 1300.0% to 0.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.07%, marking a year-over-year increase of 1300.0%. This contributed to the annual value of 0.1% for FY2024, which is 400.0% down from last year.
  • According to the latest figures from Q3 2025, Kiniksa Pharmaceuticals International's Return on Capital Employed is 0.07%, which was up 1300.0% from 0.01% recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Return on Capital Employed peaked at 0.09% during Q2 2023, and registered a low of 0.79% during Q4 2021.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.06% (2023), whereas its average is 0.15%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first skyrocketed by 8100bps in 2022, then crashed by -1500bps in 2024.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Return on Capital Employed (Quarter) stood at 0.79% in 2021, then skyrocketed by 103bps to 0.02% in 2022, then plummeted by -341bps to 0.06% in 2023, then plummeted by -71bps to 0.1% in 2024, then surged by 169bps to 0.07% in 2025.
  • Its Return on Capital Employed stands at 0.07% for Q3 2025, versus 0.01% for Q2 2025 and 0.03% for Q1 2025.